Assessment of a patient for NALFD, like assessments for other diseases with increasing incidences, must take into account the epidemiological background of each patient, and, although it is obviously important when there is risk of metabolic disease and progression to cirrhosis, assessment must also consider whether or not resource use is excessive when it is done for patients for whom an in-depth study of NALFD will not change morbidity or mortality.
La evaluación del NAFLD, al igual que la de otras enfermedades con creciente incidencia, debe realizarse teniendo en cuenta el trasfondo epidemiológico de cada paciente.